4Norrby S R,Newell P A,Faulkner.Safety profile of meropenem: in- ternational clinical experience based on the first 3 125 patients treated with meropenem[J].J Antimicrob Chem,1995,36(Suppl A): 207-223.
5Norrby S R.How adequate are the new guidelines on clinical evalu- ation of bacteriological outcome in uncomplicated UTI[J].Int J Antimicrob, 1999,11(3/4): 183-184.
6Ste'qen J,Balogh,Edward B, et al.Characteristics of mercury speci- ation in minnesota rivers and streams[J].Envir Poll ,2008,154(1): 3-11.
7Almyroudis N G,Sutton D A, Linden P, et al.Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature[J].Am J Transpl, 2006,6(10):2365-2374.
8Jaruratanasirikul S. Comparison of the Pharmacodynamics of Meropenem in Patients with Ventilator-Associated Pneumonia following Administration by 3-Hour Infusion or Bolus Injection[J]. Antimicr Agents Chemother, 2005,49 (4) : 1337-1339.
